NASDAQ$TCRX
Tscan Therapeutics Inc · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Reported financial results for the first quarter ended March 31, 2022.
TScan Therapeutics reported a net loss of $16.2 million for the first quarter ended March 31, 2022, with cash and cash equivalents of $140.8 million, sufficient to fund operations into 2024. Revenue for the quarter was $3.0 million, driven by research activities related to the collaboration agreement with Novartis.
- Ended the first quarter with cash and cash equivalents of $140.8 million, funding operations into 2024.
- Phase 1 umbrella trial for leukemia program on track to initiate in the first half of 2022.
- To present preclinical data at the American Society of Gene & Cell Therapy 25th Annual Meeting.
- Revenue for the first quarter ended March 31, 2022, was $3.0 million.
Headline financials
Revenue & EPS history
Tscan Therapeutics · Revenue · Quarterly
$3.02M
Revenue by segment
Tscan Therapeutics · $3M total across 1 segment · Q1 2022
- Collaboration & License$3M+48.0%100.0%
Forward guidance
TScan Therapeutics is focused on advancing its leukemia and solid tumor programs, with anticipated milestones including initiating a Phase 1 umbrella trial, presenting clinical and preclinical data, and submitting IND applications.
Tailwinds
- Initiate Phase 1 umbrella trial for TSC-100, with plans to enroll patients in the first half of 2022 in the TSC-100 and standard-of-care arms.
- Anticipate presentation of initial clinical data from both treatment arms of the leukemia program at a medical meeting in the second half of 2022.
- Present initial preclinical data on the TSC-200 series at the ASGCT 25th Annual Meeting.
- Progress IND-enabling studies for the TSC-200 series and submit two IND applications during the second half of 2022. These are expected to include TSC-200-A02 for HPV and TSC-204-C7 for MAGE-A1.
- In 2023, the Company plans to release initial clinical data for the TSC-200 series TCRs, as well as file further INDs for additional programs in this series.
Headwinds
- As previously disclosed, the FDA placed a clinical hold on the IND for TSC-101 in January 2022.
- The Company has since received written communication from the FDA asking for additional assessment of the potential for off-tumor reactivity in certain tissues.
- TScan is working with the agency to resolve its questions as quickly as possible.
- Pending acceptance from the FDA regarding the IND for TSC-101, the Company will then initiate the TSC-101 arm of this trial in the same patient population.
- Research is continuing into potential T cell focused COVID-19 vaccine constructs utilizing TScan’s novel T cell target discoveries. The Company is currently conducting preclinical studies for this program.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2022
+1.6%
Avg return
Earnings day
+0.2%
Avg return
5 days after
-5.7%
Avg return
30 days after
60%
12 / 20 earnings
Positive
+32.4%
Q1 2023
Best reaction
-18.2%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.3% | -3.3% | -18.9% | |
| Q4 2025 | +4.9% | +19.8% | -2.4% | |
| Q3 2025 | +0.8% | -20.5% | -17.2% | |
| Q2 2025 | +3.1% | +11.8% | +14.9% | |
| Q1 2025 | -4.6% | +0.8% | +18.3% | |
| Q4 2024 | +2.6% | +7.7% | -7.1% | |
| Q3 2024 | -7.9% | -22.6% | -47.0% | |
| Q2 2024 | -1.0% | -3.0% | -3.9% | |
| Q1 2024 | +16.3% | +16.2% | +14.9% | |
| Q4 2023 | +1.6% | -6.7% | +0.9% | |
| Q3 2023 | +3.0% | +14.9% | +50.8% | |
| Q2 2023 | -4.2% | -2.3% | +12.1% | |
| Q1 2023 | +32.4% | +18.5% | -14.4% | |
| Q4 2022 | -8.5% | -23.0% | -33.3% | |
| Q3 2022 | -0.4% | +3.9% | -20.6% | |
| Q2 2022 | -10.8% | -18.8% | -20.5% | |
| Q1 2022 | +10.6% | +38.3% | +80.0% | |
| Q4 2021 | +7.8% | -1.6% | -37.8% | |
| Q3 2021 | +2.2% | -4.4% | -28.0% | |
| Q2 2021 | -18.2% | -21.7% | -53.7% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro